Mr. Michael Frank reports

REVIVE THERAPEUTICS PROVIDES UPDATE OF KEY NERVE AGENT COUNTERMEASURE STUDY

Revive Therapeutics Ltd. is releasing an update on its research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada -- Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical countermeasures. DRDC is evaluating pharmacological compounds, including Bucillamine, that may mitigate nerve agent-induced brain injury.

After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January, 2026. Any findings from the study will be released only with the express authorization of DRDC. Revive will continue to provide updates on the DRDC study as it advances toward completion.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the U.S. government.

We seek Safe Harbor.